Biotech vet Troy Wilson shines a spotlight on his oligonucleotide startup as Eli Lilly signs up for a premier Big Pharma partnership

Troy Wilson is best known now for his role leading Kura Oncology, where the team has been developing targeted cancer drugs. Not so well known is Avidity Biosciences, which he and Kent Hawryluk founded in La Jolla about 6 years ago, using an antibody conjugated with oligonucleotides and siRNA payloads to hit specific targets of their own. 

But today they’d like to shed some of that low profile with a premier discovery partnership with Eli Lilly that will bring a much brighter spotlight to the work they’re doing.

Troy Wilson

Lilly is fronting their new alliance with $35 million in cash — $20 million upfront and $15 million for equity — along with a bounty of p

Click to view original post

Advertise With Us